Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients

Table 2 Univariate and multivariate analyses of progression-free survival in advanced gastric cancer patients receiving immunotherapy and chemotherapy

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (≥ 60vs. < 60 years)	1.210 (0.856–1.712)	0.280
Sex (male vs. female)	0.802 (0.538–1.195)	0.278
Drinking history (yes vs. no)	0.986 (0.678–1.435)	0.942
ECOG PS (0–1 vs. 2)	0.798 (0.566–1.124)	0.197
Stage (III vs. IV)	0.723 (0.497–1.052)	0.090
Differentiation (well or moderate vs. poor)	1.157 (0.806–1.662)	0.430
PD-1⁺CD8⁺Tn % (< 21.5 vs. ≥ 21.5)	1.273(0.901–1.797)	0.171
PD-L1 CPS (< 5 vs. ≥ 5)	3.538(2.297–5.450)	< 0.001	3.052 (1.909–4.879)	< 0.001
PD-1⁺CD8⁺T % (< 21.0 vs. ≥ 21.0)	9.178(5.592–15.06)	< 0.001	8.124 (4.532–14.56)	< 0.001
PD-1⁺CD8⁺Tm % (< 64.3 vs. ≥ 64.3)	4.096 (2.740–6.121)	< 0.001	3.551 (2.077–6.070)	< 0.001
PD-1⁺CD8⁺T/PD-1⁺CD4⁺T ratio(< 0.669 vs. 0.669)	2.137 (1.500–3.043)	< 0.001	1.780 (1.178–2.690)	0.006

PD-1⁺CD8⁺T PD-1⁺CD8⁺ T cells, PD-1⁺CD8⁺Tm memory PD-1⁺CD8⁺ T cells, PD-1⁺CD4⁺T PD-1⁺CD4⁺ T cells, CPS combined positive score, ECOG PS Eastern Cooperative Oncology Group Performance Status

ISSN: 1475-2867